Antibody-SN-38 Immunoconjugate Dosing for Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-camptothecin conjugates face challenges such as insolubility, structural modification complexity, lactone ring instability, and pH incompatibility, leading to reduced efficacy and increased toxicity in therapeutic applications, particularly in human cancer treatment.
Innovation Solution
Development of immunoconjugates with optimized dosages and administration schedules for antibody-SN-38 conjugates, utilizing intracellularly-cleavable linkages and specific antibodies like hMN-14, hMN-3, hMN-15, hRS7, hLL1, hLL2, and hL243, to enhance targeting and delivery of SN-38, minimizing systemic toxicity and maximizing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody-camptothecin conjugates are developed for targeted cancer therapy, then therapeutic efficacy is improved, but systemic toxicity increases
Solution Approach 1:
The patent segments the therapeutic agent into two parts: a stable antibody component for targeted delivery and a camptothecin component for cytotoxic activity. The antibody-camptothecin conjugate structure separates the targeting function (antibody) from the therapeutic function (camptothecin), allowing selective delivery to cancer cells while reducing systemic exposure and toxicity.
Solution Approach 2:
The patent uses a linker as an intermediary component connecting the antibody and camptothecin. This linker serves as a mediator that stabilizes the camptothecin lactone ring during circulation while enabling intracellular release of the active drug, thus protecting the therapeutic agent from premature degradation and reducing systemic toxicity.
2Power
If camptothecin derivatives are used as therapeutic agents, then antitumor potency is improved, but solubility and stability deteriorate
Solution Approach 1:
The linker acts as an intermediary that protects the camptothecin lactone ring from opening during circulation. The linker's chemical structure is designed to maintain the lactone ring in its closed, active form while allowing intracellular enzymes to trigger ring opening and drug release, thus stabilizing the potent but unstable camptothecin derivative.
Solution Approach 2:
The patent modifies the chemical parameters of camptothecin by conjugating it to an antibody through a specifically designed linker. This parameter change (conjugation) improves the stability of the lactone ring and enhances solubility while maintaining the high antitumor potency of the camptothecin moiety.
3Ease of operation
If conventional dosing schedules are used for immunoconjugates, then administration simplicity is maintained, but therapeutic optimization is lost
Solution Approach 1:
The patent implements periodic dosing schedules for the immunoconjugate, administering the drug at optimized intervals (e.g., every 2 weeks or every 3 weeks). This periodic action allows the antibody to accumulate in tumor tissue over time while permitting normal tissue recovery, thereby optimizing therapeutic effect without requiring complex continuous infusion protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized immunoconjugates demonstrate superior efficacy in treating resistant cancers with reduced toxicity, achieving significant tumor shrinkage and improved tolerability, even at high doses, overcoming resistance to standard therapies like irinotecan.
Implementation Method 1
the antibodies and therapeutic moieties are linked via an intracellularly-cleavable linkage that increases therapeutic efficacy
Data Source
AI summary
The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.